Lonza to produce talactoferrin for Agennix
Potential treatment for NSCLC is currently in Phase III trials
Lonza has agreed to produce talactoferrin, an oral Dendritic Cell Mediated Immunotherapy (DCMI), for Agennix of Germany.
The potential treatment for nonsmall cell lung cancer (NSCLC) is currently in Phase III testing.
Under the agreement, Lonza will produce commercial material at its microbial manufacturing facility in Kouřim, Czech Republic.
According to Lonza, this agreement initiates the process needed ultimately to seek approval for the Swiss firm to be a second manufacturer of talactoferrin after the initial commercial launch.
‘We are committed to supporting emerging therapeutics through clinical trial milestones,’ said Stephan Kutzer, coo at Lonza Custom Manufacturing. ‘Our partnership with Agennix is an example of this commitment and demonstrates Lonza’s ability to offer access to our development and manufacturing expertise at an early stage of production.’
Rajesh Malik, chief medical officer and management board member of Agennix, said: ‘In anticipation of positive Phase III data and a potential product approval, it is important that we have more than one manufacturer in place to ensure we can meet anticipated commercial demand and that we have security of supply.’
